Welcome to our dedicated page for ALTERITY THERAPEUTICS SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
ALTERITY THERAPEUTICS LTD (ATHE) director Peter Ashley Marks reported related transactions on August 31, 2026 through Lampam Pty Ltd. An entity associated with him bought 47,620 ordinary shares at $0.50 per share, bringing its indirect holdings to 191,340 ordinary shares, and disposed of 47,620 listed options with a $0.50 exercise price expiring August 31, 2026.
ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.
Alterity Therapeutics Limited (ATHE) reports that it has completed the issue of 8,400,000 fully paid ordinary shares to MST Financial Services Pty Ltd and various sub-underwriters. The shares were issued pursuant to an underwriting agreement relating to Alterity’s ATHO class of listed options exercisable at A$0.50 each on or before August 31, 2026.
The company has provided a cleansing notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), which facilitates secondary trading of these newly issued shares in compliance with Australian securities law.
ALTERITY THERAPEUTICS LTD (ATHE) reports that CEO David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026 at 10:20 a.m. ET, with a live and archived webcast available via the company’s investor website.
Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, focusing on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in advanced MSA.
ALTERITY THERAPEUTICS LTD (ATHE) entered into an Underwriting Agreement with MST Financial Services Pty Ltd, which has agreed to underwrite the exercise of up to 8,400,000 unexercised ATHO listed options ahead of their expiry. These Underwritten Options are expected to raise approximately A$4.2 million before costs.
There are currently 15,918,235 ATHO options on issue, exercisable at A$0.50 and expiring at 5:00pm (AEST) on 31 August 2026. Subject to completion of the underwriting and depending on how many options are exercised by holders, Alterity will issue between 8,400,000 and 15,918,235 new shares and raise approximately A$4.2–7.96 million before costs.
The underwriter will receive a 7% fee on gross proceeds from underwritten option exercises and may allocate Underwritten Shares to sub-underwriters that are sophisticated and professional investors. Proceeds are expected to support late-stage clinical development of ATH434 in Multiple System Atrophy and general working capital. The agreement includes customary conditions and termination events and may be terminated by either party in specified circumstances.
ALTERITY THERAPEUTICS LTD (ATHE) reports that it has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the U.S. Securities and Exchange Commission. The report and related XBRL interactive data are available on the company’s website, and shareholders can request a hard copy free of charge.
Alterity describes itself as a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, following clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data from an open-label Phase 2 trial in advanced MSA.